|Mr. Jean-Paul Clozel M.D.||CEO & Director||N/A||N/A||1955|
|Mr. AndrÃ© C. Muller||Exec. VP & CFO||N/A||N/A||1963|
|Dr. Martine Clozel||Exec. VP & Chief Scientific Officer||N/A||N/A||1955|
|Mr. Andrew C. Weiss||Sr. VP and Head of Investor Relations & Corp. Communications||N/A||N/A||1968|
|Mr. Oliver Peinelt||Sr. VP & Group Gen. Counsel||N/A||N/A||1970|
|Mr. Alexander Khatuntsev||Sr. VP & Head of HR||N/A||N/A||1978|
|Dr. Guy Braunstein||Exec. VP & Head of Global Clinical Devel.||N/A||N/A||1956|
|Mr. Simon Jose||Exec. VP & Chief Commercial Officer||N/A||N/A||N/A|
|Mr. Olivier Lambert||Sr. VP & Head of Pharmaceutical Devel.||N/A||N/A||1966|
|Mr. Markus A. Riederer||Sr. VP & Head of Drug Discovery Biology||N/A||N/A||1962|
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Idorsia Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.